Skip to content

Study · Observational study · n = 333 · 2001

11 results

Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report.

Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P

Human reproduction (Oxford, England)1 Aug 2001Cited by 40 (Europe PMC)

PMID11473947 (opens in a new tab)DOI10.1093/humrep/16.8.1588 (opens in a new tab)PepBankPUB-11473947
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyEfficacy outcome

    After ganirelix IVF stimulation, 68 vital intrauterine pregnancies resulted in 46 singleton deliveries, 12 twin deliveries and one triplet delivery.

    In plain wordsAfter ganirelix IVF stimulation, 68 vital intrauterine pregnancies resulted in singleton, twin and triplet deliveries.

    Peptide
    Ganirelix
    Outcome
    Not applicablePregnancies and delivery plurality
    Study

    n = 333

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Vital intrauterine pregnancies
    68 pregnancies
    ganirelix dose-finding cohort
    Singleton births
    46 singletons
    ganirelix dose-finding cohort
    Twin births
    12 twins
    ganirelix dose-finding cohort
    Triplet births
    1 triplet
    ganirelix dose-finding cohort

    Source sentences

    Summary
    In total, 68 vital intrauterine pregnancies were established that resulted in the birth of 46 singletons, 12 twins and one triplet.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  2. 02HumanObservational studySafety outcome

    Among 67 followed pregnant patients after ganirelix IVF stimulation, six miscarriages occurred (9%).

    In plain wordsAfter ganirelix IVF stimulation, six of 67 followed pregnant patients had miscarriages.

    Peptide
    Ganirelix
    Outcome
    Not applicableMiscarriages
    Study

    n = 67

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Miscarriages
    6 miscarriages
    of 67 followed pregnant patients
    Miscarriage proportion
    9%
    of 67 followed pregnant patients

    Source sentences

    Summary
    Follow-up of the 67 pregnant patients (one subject was lost to follow-up) revealed six miscarriages (9%).
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  3. 03HumanObservational studySafety outcome

    Among 61 ongoing pregnancies after ganirelix IVF stimulation, one singleton pregnancy ended in spontaneous abortion in week 19.

    In plain wordsAfter ganirelix IVF stimulation, one singleton pregnancy ended in spontaneous abortion in week 19.

    Peptide
    Ganirelix
    Outcome
    Not applicableSpontaneous abortion at week 19
    Study

    n = 61

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Spontaneous abortion
    1 pregnancy
    singleton pregnancy, of 61 ongoing pregnancies
    Gestational week of spontaneous abortion
    19 weeks
    singleton pregnancy

    Source sentences

    Summary
    Of the 61 subjects with an ongoing pregnancy, two with a singleton pregnancy did not give birth to a live-born infant (one spontaneous abortion in week 19, and one intrauterine death in week 27).
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  4. 04HumanObservational studySafety outcome

    Among 61 ongoing pregnancies after ganirelix IVF stimulation, one singleton pregnancy ended in intrauterine death in week 27.

    In plain wordsAfter ganirelix IVF stimulation, one singleton pregnancy ended in intrauterine death in week 27.

    Peptide
    Ganirelix
    Outcome
    Not applicableIntrauterine death at week 27
    Study

    n = 61

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Intrauterine death
    1 pregnancy
    singleton pregnancy, of 61 ongoing pregnancies
    Gestational week of intrauterine death
    27 weeks
    singleton pregnancy

    Source sentences

    Summary
    Of the 61 subjects with an ongoing pregnancy, two with a singleton pregnancy did not give birth to a live-born infant (one spontaneous abortion in week 19, and one intrauterine death in week 27).
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  5. 05HumanObservational studySafety outcome

    After ganirelix IVF stimulation, mean gestational age for singleton pregnancies was 39.4 weeks.

    In plain wordsAfter ganirelix IVF stimulation, singleton pregnancies had a mean gestational age of 39.4 weeks.

    Peptide
    Ganirelix
    Outcome
    Not applicableSingleton gestational age
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Mean gestational age
    39.4 weeks
    singleton pregnancies

    Source sentences

    Summary
    The mean gestational age was 39.4 weeks for singleton pregnancies, and 36.6 weeks for multiple pregnancies.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  6. 06HumanObservational studySafety outcome

    After ganirelix IVF stimulation, mean gestational age for multiple pregnancies was 36.6 weeks.

    In plain wordsAfter ganirelix IVF stimulation, multiple pregnancies had a mean gestational age of 36.6 weeks.

    Peptide
    Ganirelix
    Outcome
    Not applicableMultiple pregnancy gestational age
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Mean gestational age
    36.6 weeks
    multiple pregnancies

    Source sentences

    Summary
    The mean gestational age was 39.4 weeks for singleton pregnancies, and 36.6 weeks for multiple pregnancies.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  7. 07HumanObservational studyEfficacy outcome

    After ganirelix IVF stimulation, 73 infants were born, including 33 boys and 40 girls.

    In plain wordsAfter ganirelix IVF stimulation, 73 infants were born, including 33 boys and 40 girls.

    Peptide
    Ganirelix
    Outcome
    Not applicableInfants born
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Infants born
    73 infants
    ganirelix dose-finding cohort
    Boys born
    33 boys
    ganirelix dose-finding cohort
    Girls born
    40 girls
    ganirelix dose-finding cohort

    Source sentences

    Summary
    In total, 73 infants (33 boys, 40 girls) were born.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  8. 08HumanObservational studySafety outcome

    After ganirelix IVF stimulation, birth weight below 2500 g occurred in 8.7% of infants from singleton deliveries.

    In plain wordsAfter ganirelix IVF stimulation, 8.7% of singleton infants weighed below 2500 g.

    Peptide
    Ganirelix
    Outcome
    Not applicableSingleton low birth weight
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Infants with birth weight <2500 g
    8.7%
    infants from singleton deliveries

    Source sentences

    Summary
    A birth weight <2500 g was reported for 8.7% and 54.2% of the infants resulting from singleton and twins delivery respectively.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  9. 09HumanObservational studySafety outcome

    After ganirelix IVF stimulation, birth weight below 2500 g occurred in 54.2% of infants from twin deliveries.

    In plain wordsAfter ganirelix IVF stimulation, 54.2% of twin infants weighed below 2500 g.

    Peptide
    Ganirelix
    Outcome
    Not applicableTwin low birth weight
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Infants with birth weight <2500 g
    54.2%
    infants from twin deliveries

    Source sentences

    Summary
    A birth weight <2500 g was reported for 8.7% and 54.2% of the infants resulting from singleton and twins delivery respectively.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  10. 10HumanObservational studySafety outcome

    After ganirelix IVF stimulation, one boy had Beckwith-Wiedemann syndrome with exomphalos and macroglossia, classified as a major congenital malformation.

    In plain wordsAfter ganirelix IVF stimulation, one boy had a major congenital malformation, Beckwith-Wiedemann syndrome.

    Peptide
    Ganirelix
    Outcome
    Not applicableMajor congenital malformation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Major congenital malformation
    1 malformation
    ganirelix dose-finding cohort

    Source sentences

    Summary
    One major congenital malformation was diagnosed; a boy with Beckwith-Wiedemann syndrome (exomphalos and macroglossia).
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.
  11. 11HumanObservational studySafety outcome

    After ganirelix IVF stimulation, seven minor malformations occurred among five infants.

    In plain wordsAfter ganirelix IVF stimulation, seven minor malformations occurred among five infants.

    Peptide
    Ganirelix
    Outcome
    Not applicableMinor malformations
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.0625-2 mgAs given in this study (human).

    Measurements

    Minor malformations
    7 malformations
    ganirelix dose-finding cohort
    Infants with minor malformations
    5 infants
    ganirelix dose-finding cohort

    Source sentences

    Summary
    Seven minor malformations were reported among five infants.
    2 context sentences
    Summary · context
    This preliminary report includes follow-up data of patients treated with the GnRH antagonist, ganirelix, during ovarian stimulation for IVF or ICSI.
    Summary · context
    In total, 333 patients were randomized in a multicentre, double-blind, dose-finding study of ganirelix, at six different doses ranging from 0.0625 to 2 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.